Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues
Illumina (NASDAQ:ILMN) and the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark partner to explore the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. One of the first projects of its kind worldwide, the endeavor aims to acquire new knowledge in terms of the medical and biological understanding of special factors underlying the development of human neuropsychiatric diseases through the ages. Ultimately, the project may provide a new approach to the development of medicines and other therapeutic treatments for mental and neurological conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005867/en/
Where do brain disorders come from? In an effort to shed light on the role of microbes in the pathogenesis of neuropsychiatric illnesses, such as Alzheimer’s disease and schizophrenia, Professor Eske Willerslev and his team will build one of the largest genomic datasets of its kind, by complete DNA mapping of thousands of ancient Eurasian human remains. The data will be obtained from bones and teeth, the oldest remains dating back 10,000 years.
The international, multi-disciplinary team of scientists, which includes specialists in ancient genomics, neuro-genetics, population genetics, archaeology, linguistics, and experts in brain health, among others, will focus on creating two unique subsets of genomic data. The first panel is a 5,000 ancient human genomes panel. The second panel will consist of ancient pathogen DNA that is associated with human diseases. Both panels, which will be made publicly available, will together advance our understanding of the evolution of disease variance and its interaction with the human genome and pathogen pressure. The project will generate and analyze one of the largest sets of ancient human and pathogen genome panels ever created.
“Over the past 10,000 years, mankind has experienced some of the greatest lifestyle changes in the history of our species,” said Professor Willerslev, Lundbeck Foundation Professor at the University of Copenhagen and Prince Philip Professor at the University of Cambridge. “Our diet changed as we developed from hunter-gatherers into farmers, our settlement patterns changed, and there have been changes in pressure of infection from the pathogenic micro-organisms to which we were exposed due to altered living conditions. We also know that chronic viral, bacterial and fungal infections might be causative factors in neuropsychiatric diseases, so there is every reason to believe that the analyses of DNA from this period will show significant trends, giving us the ability to create new, publicly available reference sets, to enhance both the scientific and healthcare communities’ understanding of disease evolution.”
In order to decode the genetic origins and evolution of human diseases, Professor Willerslev and his team will utilize Illumina’s most powerful sequencer, the NovaSeq™6000 System, which was designed to open new horizons for larger, more robust experiments, providing the throughput to properly power large-cohort studies. Projects of this scale benefit from speed, throughput and data quality, and as such this project will leverage the S4 flow cell to sequence up to 20 billion ancient DNA fragments every two days.
“The NovaSeq 6000 was the obvious choice for this project with its unrivaled data quality and high-throughput capabilities,” remarks Professor Willerslev. “While we conceived this project to explore the evolutionary origins of genetic disorders years ago, it was simply impossible to realize before Illumina’s NovaSeq System came on the market. We are delighted that Lundbeck Foundation had the foresight to see the importance of our project and that Illumina’s technology will make the research possible.”
“Illumina is thrilled to be working with Professor Willerslev and his team on this extraordinary project,” said Paula Dowdy, Senior Vice President and General Manager for Europe, Middle East and Africa at Illumina. “It will be extremely valuable, if by going back 10,000 years, we can acquire new information about when, and under which environmental conditions, a brain disorder may have been introduced into human DNA. This project has the potential to influence future product developments in genetics and precision medicine by providing invaluable insights to those affected by mental health issues.”
To learn more, please visit the Illumina News Center:
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
About the Lundbeck Foundation GeoGenetics Centre
The Lundbeck Foundation GeoGenetics Centre for Brain, Disease & Evolution is a world-class Centre of excellence for ancient DNA research in humans, pathogens and environmental DNA. The GeoGenetics Centre was founded in 2009 as a Danish National Research Foundation Centre of excellence, and now continues with generous funding from Lundbeck Foundation, Carlsberg Foundation, Novo Nordisk Foundation, and the Wellcome Trust. The GeoGenetics Centre is cross-disciplinary, hosting scientists from a broad array of disciplines and from around the world. Located at the University of Copenhagen, Denmark, we explore human migration, disease evolution, adaptations to lifestyle changes and language development in our efforts to understand who we are, where we came from and where we are headed. Our goals are to increase our mutual appreciation for what it means to be human as well as to decrease suffering through understanding disease etiologies and respecting our diversity.
This release contains projections, information about our financial outlook, total addressable market, and other forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to further develop and commercialize our instruments and consumables and to deploy new products, including diagnostic assays, services and applications, and expand the markets for our technology platforms; (ii) our ability to manufacture robust instrumentation, consumables, including diagnostic assays; (iii) our ability to successfully identify and integrate acquired technologies, products or businesses; (iv) the future conduct and growth of the business and the markets in which we operate; (v) challenges inherent in developing, manufacturing, and launching new products and services or integrating acquired products and technology into our portfolio; (vi) our ability to obtain necessary regulatory approvals to close the transaction described or to market and sell diagnostic or therapeutic products and (vii) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AnyVision Closes $74 Million Series A with New Participation from M12 and DFJ Growth18.6.2019 11:10:00 CEST | Pressemelding
AnyVision, a leading computer vision company specializing in face, body, and object-recognition software, today announced the close of its $74 million Series A financing round. New investment comes from M12, Microsoft’s venture fund, DFJ Growth and OG Technology Partners. As part of the Series A, AnyVision previously announced investment from LightSpeed Venture Partners, Robert Bosch GmbH, Qualcomm Ventures, and Eldridge Industries. AnyVision, founded in 2015, is a leading computer vision company specializing in face, body, and object-recognition software. AnyVision develops core software solutions that make all cameras smart. These solutions are agnostic to all cameras, computing frameworks, and use-cases. “There are very few times in business when you have the opportunity to build an entirely new industry alongside leading ecosystem players,” said Eylon Etshtein, CEO and Co-Founder of AnyVision. “We are fortunate to have the backing of chipmakers like Qualcomm, camera manufacturers s
IDEMIA Launches Augmented Vision, its Next Generation Video Analytics Application at IFSEC International18.6.2019 11:07:00 CEST | Pressemelding
IDEMIA, the global leader in Augmented Identity, launches its video analytics application enhancing security in public and private places. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190618005513/en/ Credits: IDEMIA Augmented Vision supports security officers in identifying persons of interest in real-time, and helps speed up post-event investigations. This latest cutting-edge technology from IDEMIA will enhance security in transport hubs (airports, stations…), stadiums and arenas, retail and commercial buildings, as well as gaming and entertainment sites that face growing security challenges. The application is based on IDEMIA’s long-standing expertise in deep learning and biometrics for video and image analysis including IDEMIA’s facial recognition technology: a longstanding best-in-class combination of efficiency, scalability and accuracy for facial recognition as evidenced by IDEMIA’s leading position in the most rece
F-star Appoints Darlene Deptula-Hicks as Chief Financial Officer and Opens Office in Cambridge, MA18.6.2019 11:00:00 CEST | Pressemelding
F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, today announces the appointment of Darlene Deptula-Hicks, MBA as Chief Financial Officer (CFO), succeeding Tolga Hassan, who is appointed to serve as F-star’s Chief Operating Officer. Darlene Deptula-Hicks joins F-star from Northern Biologics, Inc., a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody therapeutics in oncology. Previously, Darlene held CFO positions across both private and publicly listed US companies, including Pieris Pharmaceuticals Inc., Microline Surgical Inc. and T2 Biosystems Inc. She brings to F-star a proven track record of finance strategy and leadership, capital raising, industry knowledge and the ability to build strong strategic partnerships. Darlene Deptula-Hicks, CFO of F-star, said: “It is a very exciting time to be joining F-star given its evolution to a f
Norsk Titanium Receives Airbus Contract for Qualification and Production18.6.2019 10:00:00 CEST | Pressemelding
Officials with Norsk Titanium (Norsk) announce today a contract award from Airbus for the Qualification and Serial Production of the first parts to be manufactured utilizing wire-based Direct Energy Deposition (DED) additive manufacturing technology. “We have worked closely with Airbus over several years to demonstrate the technological maturity and the industrial readiness of our Rapid Plasma Deposition™ (RPD™) process,” said Norsk President and CEO Michael Canario. “This contract award is structured to enable long-term, serial production immediately following qualification. Our Plattsburgh, New York facility, with the assistance of Airbus technical leadership, has been preparing for this moment and is eager to demonstrate a 21st century advanced additive manufacturing capability.” This qualification of Airbus parts will demonstrate the suitability of the DED additive manufacturing process for aircraft structural parts. It will formalize the process by which individual parts are produ
Axonics® Announces U.S. Food & Drug Administration Approves Use of Full-Body MRI for Pivotal Study Patients18.6.2019 10:00:00 CEST | Pressemelding
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the U.S. Food & Drug Administration (“FDA”) approved the use of full-body magnetic resonance imaging (“MRI”) using 1.5 Tesla MRI scanners for clinical study patients implanted with the Axonics System. The approval was a result of a supplement filed by Axonics with the FDA under the Investigational Device Exemption (“IDE”) regarding the Company’s ARTISAN-SNM 129-patient pivotal clinical study. The FDA concluded that Axonics provided sufficient data to support full-body MRIs. Raymond W. Cohen, CEO of Axonics, commented, “Allowing full-body MRI scans for our clinical study patients means that none will have to undergo an explant of their neurostimulator device should they require an MRI. We view this as a very positive step by the FD
Innovusion Announces Its High-Resolution Image-Grade LiDAR System “Cheetah”, Enabling the Safest Performance in the Vehicle Mobility Industry18.6.2019 09:00:00 CEST | Pressemelding
Innovusion Inc., the worldwide leader in the design and development of innovative hybrid Solid State LiDAR systems for vehicle safety applications, has announced the availability of its Cheetah system. Based on its innovative rotating polygon optical architecture, Innovusion has melded together proprietary detector electronics, advanced optics and sophisticated software algorithms to offer a system that has no equal in the long-distance, high-resolution LiDAR vehicle mobility system industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190618005066/en/ Innovusion's Cheetah long-distance LiDAR System...the safest in the mobility safety industry (Graphic: Business Wire) Smart architecture, streamlined optics design, and integrated optical paths result in rapid manufacturing, scalability into automotive production, and lower cost. The ability to provide a detection range of 200 meters on objects with 10% reflectivity and cle